Multicenter Clinical Cancer Research After COVID-19: A Perspective From NRG Oncology
- PMID: 32890539
- PMCID: PMC7462891
- DOI: 10.1016/j.ijrobp.2020.06.056
Multicenter Clinical Cancer Research After COVID-19: A Perspective From NRG Oncology
Figures
Comment on
-
Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials.JAMA Netw Open. 2020 Jun 1;3(6):e2010651. doi: 10.1001/jamanetworkopen.2020.10651. JAMA Netw Open. 2020. PMID: 32478845 Free PMC article.
-
Impact of the COVID-19 crisis on imaging in oncological trials.Eur J Nucl Med Mol Imaging. 2020 Aug;47(9):2054-2058. doi: 10.1007/s00259-020-04910-y. Eur J Nucl Med Mol Imaging. 2020. PMID: 32533240 Free PMC article. No abstract available.
References
-
- Mooney M., McCaskill-Stevens W. Additional guidance regarding alternative procedures for clinical trials supported by the NCI Cancer Therapy Evaluation Program (CTEP) and NCI Community Oncology Research Program (NCORP) affected by the spread of the novel coronavirus. https://ctep.cancer.gov/investigatorResources/docs/Memorandum_on_Additio... Available at:
-
- Murthy V.H., Krumholz H.M., Gross C.P. Participation in cancer clinical trials: Race-, sex-, and age-based disparities. JAMA. 2004;291:2720–2726. - PubMed
